252 related articles for article (PubMed ID: 37321827)
21. [
Hong H; Zha Z; Zhao R; Luo Y; Jin W; Li L; Wang R; Yan L; Wang H; Ploessl K; Qiao J; Zhu L; Kung HF
Mol Pharm; 2023 Apr; 20(4):2159-2169. PubMed ID: 36942924
[TBL] [Abstract][Full Text] [Related]
22. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
[TBL] [Abstract][Full Text] [Related]
23. Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study.
Huang W; Pang Y; Liu Q; Liang C; An S; Wu Q; Zhang Y; Huang G; Chen H; Liu J; Wei W
Research (Wash D C); 2023; 6():0282. PubMed ID: 38706713
[TBL] [Abstract][Full Text] [Related]
24. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
[TBL] [Abstract][Full Text] [Related]
25. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of [
Yadav MP; Ballal S; Martin M; Roesch F; Satapathy S; Moon ES; Tripathi M; Gogia A; Bal C
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):805-819. PubMed ID: 37932560
[TBL] [Abstract][Full Text] [Related]
27. Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics.
Martin M; Ballal S; Yadav MP; Bal C; Van Rymenant Y; De Loose J; Verhulst E; De Meester I; Van Der Veken P; Roesch F
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980775
[TBL] [Abstract][Full Text] [Related]
28. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613
[TBL] [Abstract][Full Text] [Related]
29. Clinical translation of a novel FAPI dimer [
Tan Y; Li J; Zhao T; Zhou M; Liu K; Xiang S; Tang Y; Jakobsson V; Xu P; Chen X; Zhang J
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38561515
[TBL] [Abstract][Full Text] [Related]
30. Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin α
Liu K; Jiang T; Rao W; Chen B; Yin X; Xu P; Hu S
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1544-1557. PubMed ID: 38276986
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [
Huang J; Fu L; Zhang X; Huang S; Dong Y; Hu K; Han Y; Zhou K; Min C; Huang Y; Tang G
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3363-3374. PubMed ID: 37266596
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and Evaluation of
Bendre S; Zhang Z; Colpo N; Zeisler J; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110717
[TBL] [Abstract][Full Text] [Related]
33. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
[TBL] [Abstract][Full Text] [Related]
34. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Privé BM; Boussihmad MA; Timmermans B; van Gemert WA; Peters SMB; Derks YHW; van Lith SAM; Mehra N; Nagarajah J; Heskamp S; Westdorp H
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1906-1918. PubMed ID: 36813980
[TBL] [Abstract][Full Text] [Related]
36. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.
Lindner T; Loktev A; Altmann A; Giesel F; Kratochwil C; Debus J; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2018 Sep; 59(9):1415-1422. PubMed ID: 29626119
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.
Moon ES; Ballal S; Yadav MP; Bal C; Van Rymenant Y; Stephan S; Bracke A; Van der Veken P; De Meester I; Roesch F
Am J Nucl Med Mol Imaging; 2021; 11(6):476-491. PubMed ID: 35003886
[TBL] [Abstract][Full Text] [Related]
38. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.
Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS
Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492
[TBL] [Abstract][Full Text] [Related]
39. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
40.
Kratochwil C; Flechsig P; Lindner T; Abderrahim L; Altmann A; Mier W; Adeberg S; Rathke H; Röhrich M; Winter H; Plinkert PK; Marme F; Lang M; Kauczor HU; Jäger D; Debus J; Haberkorn U; Giesel FL
J Nucl Med; 2019 Jun; 60(6):801-805. PubMed ID: 30954939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
